Veeraraghavan Balaji, Pragasam Agila K, Bakthavatchalam Yamuna D, Ralph Ravikar
Department of Clinical Microbiology, Christian Medical College, Vellore 632004, Tamil Nadu, India.
Department of Medicine, Christian Medical College, Vellore 632004, Tamil Nadu, India.
Future Sci OA. 2018 Jun 26;4(6):FSO312. doi: 10.4155/fsoa-2018-0003. eCollection 2018 Jul.
Multidrug-resistant subsp. serovar Typhi (resistant to ampicillin, chloramphenicol and cotrimoxazole), was significantly reduced with the increased usage of fluoroquinolones and azithromycin. This has led to declining multidrug resistance rates in India with increasing ciprofloxacin nonsusceptibility rates and clinical failures due to azithromycin. However, for the available agents such as ceftriaxone, azithromycin and fluoroquinolones, the dose and duration for treatment is undefined. The ongoing clinical trials for typhoid management are expected to recommend the defined dose and duration for better clinical outcome. We made an attempt to summarize the issues in laboratory detection, treatment options and responses, and the concerns in clinical practice seen in the developing countries.
耐多药伤寒杆菌亚种血清型伤寒杆菌(对氨苄西林、氯霉素和复方新诺明耐药),随着氟喹诺酮类药物和阿奇霉素使用量的增加而显著减少。这导致印度耐多药率下降,但环丙沙星不敏感率和阿奇霉素导致的临床治疗失败率却在上升。然而,对于头孢曲松、阿奇霉素和氟喹诺酮类等现有药物,治疗的剂量和疗程尚未明确。正在进行的伤寒治疗临床试验有望推荐明确的剂量和疗程,以获得更好的临床疗效。我们试图总结发展中国家在实验室检测、治疗选择和反应以及临床实践中所面临的问题。